Mavoglurant

DB13004InvestigationalSmall molecule

Mavoglurant has been used in trials studying the treatment of Patient Diagnosed With OCD and and Resistant to SSRI Treatment (Failed SSRI Over 12 Weeks at Appropriate Doses).

Mechanism: Pharmacologically active on Metabotropic glutamate receptor 5
Curator reviewed
Formula / weight: C₁₉H₂₃NO₃ · 313.397 g/mol (avg)
Code names: AFQ-056

Resolves to

Compound

UNIIGT0I9SV4F6CAS543906-09-8ChEMBLCHEMBL3087515PubChem9926832

Structure

InChIKeyZFPZEYHRWGMJCV-ZHALLVOQSA-NSMILESCOC(=O)N1CC[C@@H]2[C@H]1CCC[C@@]2(O)C#CC1=CC(C)=CC=C1

Targets

P41594GRM5

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

20Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Mavoglurant, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account